Dr. Steven R. Schuster, M.D.

Medicare patients and services

Medicare patients, 2024

351

Services billed

1,085

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 30 payments worth $48,519 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Colorado →

Industry-funded research

Named as a principal investigator on 15 industry-funded studies in 2025, from 9 companies. The companies reported $3,389,278 in research payments for these studies, mostly to the institutions running them.

• A phase 3 openlabel study of elranatamab monotherapy versus elotuzumab pomalidomide dexamethasone epd or pomalidomide bortezomib dexamethasone pvd or carfilzomib dexamethasone kd in participants with relapsedrefractor…
  Pfizer Inc.
• A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study
  Novartis Pharmaceuticals Corporation
• A phase 12 openlabel multicenter study to evaluate a dosing regimen with two stepup priming doses and longer dosing intervals of elranatamab PF06863135 monotherapy in participants with relapsedrefractory multiple myeloma
  Pfizer Inc.
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
  Eli Lilly and Company · Active, not recruiting · NCT05514054
• An interventional safety and efficacy phase 1B2 openlabel study to investigate tolerability pk and antitumor activity of vepdegestrant ARV471PF07850327 an oral proteolysis targeting chimera in combination with PF07220…
  Pfizer Inc.
• Elranatamab post trial access an openlabel singlearm study for participants with multiple myeloma continuing from pfizersponsored elranatamab clinical studies
  Pfizer Inc.
• A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
  Beone Medicines USA, Inc. · Recruiting · NCT05006716
• A phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell…
  AstraZeneca UK Limited
• Tactiveu an interventional safety and efficacy phase 1B2 openlabel umbrella study to investigate tolerability pk and antitumor activity of vepdegestrant ARV471PF07850327 an oral proteolysis targeting chimera in combin…
  Pfizer Inc.
• A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
  AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Fort Collins

• Farrah Datko, MD
• Lakshmi Kolandra, D.O.
• Robert F. Marschke JR., M.D.
• Lynn Mathew, MD
• Ross W. Mcfarland, M.D.